SEC Form 4 · accession 0001209191-17-009201
Epizyme, Inc. · EPZM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert A Copeland
Officer — President of Research and CSO
Period of report
Feb 8, 2017
Accepted (ET)
Feb 9, 2017 · 5:58 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001571498
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $12.45 | Feb 8, 2017 | A | 97,659 | A | — | Feb 7, 2027 | Common Stock | 97,659 | 97,659 | D |
Explanation of responses
- F1This option was granted on February 8, 2017 pursuant to the Company's 2013 Stock Incentive Plan with respect to 97,659 shares of Common Stock, with 25% vesting on February 8, 2018 and the remaining 75% vesting in 36 substantially equal monthly installments thereafter.